BioCentury | Nov 10, 2020
Product Development

Reata, Calliditas make good on renewed interest in kidney disease with Phase III successes

Two renal diseases are on track for their first approvals after a pair of Phase III studies hit primary endpoints, suggesting renewed interest in the therapeutic area is paying off for patients and investors....
BioCentury | Nov 1, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

...neck cancer EGFR antisense RNA 1 (EGFR-AS1) Patient sample and mouse studies suggest inhibiting the long non-coding RNA (lncRNA) EGFR-AS1...
BioCentury | Oct 31, 2017
Distillery Therapeutics

Cancer

...and neck cancer Patient sample and mouse studies suggest inhibiting the long non-coding RNA (lncRNA) EGFR-AS1...
...squamous cell carcinoma of the head and neck (SCCHN). In patient samples, tumor levels of EGFR-AS1...
...LNA. Next steps could include identifying and testing EGFR-AS1 inhibitors in models of HNSCC. TARGET/MARKER/PATHWAY: EGFR antisense RNA 1 (EGFR-AS1)...
BioCentury | Mar 2, 2015
Clinical News

Astragraf XL tacrolimus: Phase IIIb data

The open-label, international Phase IIIb DIAMOND trial in 893 patients showed that once-daily low-dose (0.15-0.175 mg/kg) Advagraf in combination with Simulect basiliximab and mycophenolate mofetil (MMF) met the primary endpoint of increasing GFR as measured...
BioCentury | Feb 16, 2012
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Epidermal growth factor receptor (EGFR) Cell culture and patient studies suggest patients with colorectal cancer (CRC) who become resistant...
BioCentury | Feb 9, 2012
Cover Story

Bringing on the BRAF

The BRAF inhibitor Zelboraf vemurafenib from Daiichi Sankyo Co. Ltd. and Roche produces about an 80% response rate in its approved indication of BRAF-mutant melanoma but only about a 5% rate in colorectal tumors with...
BioCentury | Aug 1, 2011
Product Development

Simple fix for EGFR resistance

All non-small cell lung cancer patients on the EGFR inhibitors Tarceva erlotinib and Iressa gefitinib eventually develop resistance to the drugs and progress. A predictive model developed by a team of cancer researchers suggests simply...
BioCentury | Jun 25, 2011
Company News

No takers for Genmab's zalutumumab

Genmab A/S (CSE:GEN) said it will wind down its zalutumumab program after failing to partner the cancer candidate. Last year, the biotech announced plans to partner the human mAb targeting EGFR as part of a...
BioCentury | May 4, 2009
Company News

Cipla, Roche cancer, generics news

The Delhi High Court denied an appeal from Roche to reverse a 2008 decision not to grant an injunction against Cipla's generic version of Roche's Tarceva erlotinib in India. In his decision, Justice S. Muralidhar...
BioCentury | Apr 27, 2009
Product Development

BiTE and Switch

Micromet Inc. presented data last week showing that its BiTEs based on Erbitux cetuximab and Vectibix panitumumab are capable of overcoming resistance mechanisms related to K-Ras (KRAS) and BRAF that hamper both of the marketed...
Items per page:
1 - 10 of 14